| Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial F Lordick, YK Kang, HC Chung, P Salman, SC Oh, G Bodoky, G Kurteva, ... The lancet oncology 14 (6), 490-499, 2013 | 953 | 2013 |
| KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience C Bokemeyer, I Bondarenko, JT Hartmann, FG De Braud, C Volovat, ... Journal of Clinical Oncology 26 (15_suppl), 4000-4000, 2008 | 390 | 2008 |
| Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients P Ruf, M Kluge, M Jäger, A Burges, C Volovat, MM Heiss, J Hess, ... British journal of clinical pharmacology 69 (6), 617-625, 2010 | 104 | 2010 |
| MiRNA and LncRNA as potential biomarkers in triple-negative breast cancer: a review SR Volovat, C Volovat, I Hordila, DA Hordila, CC Mirestean, OT Miron, ... Frontiers in oncology 10, 526850, 2020 | 98 | 2020 |
| KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study S Negru, E Papadopoulou, A Apessos, DL Stanculeanu, E Ciuleanu, ... BMJ open 4 (5), e004652, 2014 | 51 | 2014 |
| Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. F Lordick, YK Kang, P Salman, SC Oh, G Bodoky, GP Kurteva, CD Volovat, ... Journal of Clinical Oncology 31 (15_suppl), 4021-4021, 2013 | 38 | 2013 |
| EXPAND Investigators: Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label … F Lordick, YK Kang, HC Chung, P Salman, SC Oh, G Bodoky, G Kurteva, ... Lancet Oncol 14 (6), 490-499, 2013 | 36 | 2013 |
| Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced … F Lordick, YK Kang, HC Chung, P Salman, SC Oh, G Bodoky, G Kurteva, ... Lancet Oncol 14 (6), 490-9, 2013 | 35 | 2013 |
| Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy C Volovat, IM Bondarenko, OA Gladkov, R Elsässer, A Buchner, P Bias, ... Springerplus 4, 1-11, 2015 | 32 | 2015 |
| Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy C Volovat, OA Gladkov, IM Bondarenko, S Barash, A Buchner, P Bias, ... Clinical Breast Cancer 14 (2), 101-108, 2014 | 30 | 2014 |
| Second-line chemotherapy with gemcitabine and oxaliplatin in combination with loco-regional hyperthermia (EHY-2000) in patients with refractory metastatic pancreatic cancer … C Volovat, SR Volovat, V Scripcaru, L Miron Rom Rep Phys 66 (1), 166-174, 2014 | 28 | 2014 |
| Cetuximab plus 5FU/FA/oxaliplatin (FOLFOX4) in the first-line treatment of metastatic colorectal cancer (mCRC): a large-scale phase II study, OPUS C Bokemeyer The European Cancer Conference (ECCO) 2007, 2007 | 27 | 2007 |
| Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non–small-cell lung cancer: results from the randomized controlled MONET1 study S Novello, GV Scagliotti, O Sydorenko, I Vynnychenko, C Volovat, ... Journal of Thoracic Oncology 9 (8), 1154-1161, 2014 | 21 | 2014 |
| A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer SR Volovat, TE Ciuleanu, P Koralewski, JEG Olson, A Croitoru, K Koynov, ... Oncotarget 11 (33), 3105, 2020 | 18 | 2020 |
| The results of combination of ifosfamid and locoregional hyperthermia (EHY 2000) in patients with advanced abdominal soft-tissue sarcoma after relapse of first line chemotherapy SR Volovat, C Volovat, V Scripcaru, L Miron, C Lupascu Romanian Reports in Physics 66 (1), 175-181, 2014 | 18 | 2014 |
| Theoretical model for the diclofenac release from PEGylated chitosan hydrogels D Ailincai, M Agop, IC Marinas, A Zala, SA Irimiciuc, L Dobreci, ... Drug Delivery 28 (1), 261-271, 2021 | 16 | 2021 |
| Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger … C Volovat, I Bondarenko, O Gladkov, A Buchner, A Lammerich, U Müller, ... Supportive Care in Cancer 24, 4913-4920, 2016 | 16 | 2016 |
| Oncogenic mechanisms in renal insufficiency SR Volovat, C Volovat, I Miron, M Kanbay, D Goldsmith, C Lungulescu, ... Clinical Kidney Journal 14 (2), 507-515, 2021 | 10 | 2021 |
| Radiomics in triple negative breast cancer: new horizons in an aggressive subtype of the disease CC Mireștean, C Volovăț, RI Iancu, DPT Iancu Journal of clinical medicine 11 (3), 616, 2022 | 9 | 2022 |
| Liquid Biopsy”-is it a feasible option in colorectal cancer V Scripcariu, DV Scripcariu, B Filip, MM Gavrilescu, AM Muşină, C Volovăţ Chirurgia 114 (2), 162-166, 2019 | 9 | 2019 |
